Micro Cap Research

Uncovering Value │ Delivering Insights │ Exploiting Inefficiencies

Main menu

Skip to primary content

Skip to secondary content

The Case For Micro Cap Investing
Coverage List
Market Insights
Corporate Services
Contact Us
Disclaimer

Search

Contact Us

Mail:

MicrocapResearch/FST Publishing Inc.

245 E. 63rd Street Suite 702
New York, NY 10065

Phone: 212-421-2099

Subscribe to MicrocapResearch

Email Address

Latest Articles

Online Lending Leaders: Lending Club & OnDeck September 5, 2017
Investment Conclusion The online lending industry has been red hot this bull market in terms of origination growth. Companies started coming public in 2015. The big names are Lending Club (LC) and OnDeck (ONDK). However, the post-IPO performance has been train wreck for a number of one-off reasons, pushing the valuations for these two online… […]
Q&A with Director of CMC Operations at TapImmune Inc. (TPIV), Robin McCallum July 7, 2017
Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs. Thank you, Robin, for taking part in this Q&A. First off, what are “CMC operations”, and how do they impact clinical trials and the drug development process? RM: CMC stands for Chemistry Manufacturing and Controls. CMC operations come into play when… […]
Q&A with CEO of CannaRoyalty (CNNRF), (CSE:CRZ), Marc Lustig June 20, 2017
CannaRoyalty is a fully integrated, active investor and operator in the legal cannabis sector. Our focus is building and supporting a diversified portfolio of growth-ready assets in high-value segments of the cannabis sector, including research, consumer brands, devices and intellectual property. Our management team combines a hands-on understanding of the cannabis industry with seasoned financial… […]
Q&A with new Medical Director of TapImmune (TPIV), Dr. Richard Kenney May 10, 2017
TapImmune (TPIV) is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved… […]
TapImmune (TPIV): U.S. Department of Defense Fully Funds Phase II Breast Cancer Study May 9, 2017
TapImmune (TPIV) is advancing two Phase II studies that are funded by ~$17 million in non-dilutive grants from the U.S. Department of Defense. In total, the company has 4 different Phase II studies underway and is planning to submit an Investigational New Drug (IND) Application with the FDA for another breast cancer vaccine this year. Due to the unmet… […]

The Case For Micro Cap Investing
Coverage List
Market Insights
Corporate Services
Contact Us
Disclaimer

Proudly powered by WordPress

Please wait...

Be the first to get our next great stock pick!

Get our next great stock pick in advance for FREE! Enter your name and email below. We never share email with anyone.

Submit

Don't Worry ! You will not be spammed